Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 52Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 36Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Neoplasms 29Biliary Tract Neoplasms 29Neoplasm Metastasis 28Cholangiocarcinoma 26Triple Negative Breast Neoplasms 25Pancreatic Neoplasms 25Ovarian Neoplasms 24Head and Neck Neoplasms 19Liver Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 15Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

Cisplatin 12Etoposide 11Carboplatin 9Paclitaxel 7Ifosfamide 7Filgrastim 7Bleomycin 6Radiotherapy 5Magnetic Resonance Spectroscopy 4pegfilgrastim 3Peripheral Blood Stem Cell Transplantation 3liposomal amphotericin B 2Therapeutics 2Platinum 2Ipilimumab 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Cyclophosphamide 2CTLA-4 Antigen 2tremelimumab 1sodium thiosulfate 1sargramostim 1lerisetron 1ixabepilone 1etoposide phosphate 1durvalumab 1cabozantinib 1aldesleukin 1Vinblastine 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Seminoma × durvalumab × Clear all
NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡